Respiratory Syncytial Virus (RSV) Vaccine (ResVax®)
RSV disease in infants via maternal immunization
Key Facts
Indication
RSV disease in infants via maternal immunization
Phase
Phase 3
Status
Completed (Not a current priority)
Company
About Novavax
Novavax is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel vaccines to prevent serious infectious diseases. Its core technology platform combines recombinant nanoparticle antigens with its patented saponin-based Matrix-M™ adjuvant to stimulate robust immune responses. The company achieved a major milestone with the global authorization of its COVID-19 vaccine and is now advancing a diversified pipeline targeting respiratory viruses. Novavax's strategic direction involves expanding the utility of its platform, pursuing combination vaccines, and establishing its commercial presence.
View full company profile